Abstract: A rotary piston engine is provided. The rotary piston engine includes a shell and a rotor, the rotating rotor is arranged in the shell and divides a rotor cavity into compression chambers with a variable volume, a plurality of combustion chambers rotating around a main shaft of the rotor are arranged on an outer ring of the shell, and any one of the plurality of combustion chambers is communicated with the compression chambers; the plurality of combustion chambers are in a transmission connection with the main shaft of the rotor via a transmission system, and each of the plurality of combustion chambers drives the main shaft of the rotor to rotate by a combustion of a compressed combustible gas mixture. The shell includes an upper cylinder cover and a lower cylinder cover, and a boss of the upper cylinder cover is fitted with a spigot of the lower cylinder cover.

Abstract: The present invention belongs to the field of flame arresters, and discloses a buffered wall flow multi-channels flame arrester. The flame arrester comprises a buffering and splitting cover and a Z-type wall flow multi-channels flame arresting core, wherein the buffering and splitting cover has a round-bottom plain-top cylindrical shape or hemispherical shape, with pinholes distributed in the cover surface, and channels are arranged inside the Z-type wall flow multi-channels flame arresting core. In every two adjacent channels, the inlet of one channel is blocked, and the outlet of the other channel is blocked, and in the height direction in the central cross section of the flame arresting core, pinholes are arranged in the wall surfaces between adjacent channels, and adjacent upper and lower channels constitute a fluid channel.

Abstract: Provided is a fused tri-cyclic compound as PDE3/PDE4 dual inhibitor, and a use thereof in the preparation of drugs for PDE3/PDE4 associated diseases, particularly in medicinal functions such as chronic obstructive pulmonary disease (COPD). Provided are specifically a compound of formula (I) and a pharmaceutically acceptable salt thereof.

Abstract: A rotary piston engine is provided. The rotary piston engine includes a shell and a rotor, the rotating rotor is arranged in the shell and divides a rotor cavity into compression chambers with a variable volume, a plurality of combustion chambers rotating around a main shaft of the rotor are arranged on an outer ring of the shell, and any one of the plurality of combustion chambers is communicated with the compression chambers; the plurality of combustion chambers are in a transmission connection with the main shaft of the rotor via a transmission system, and each of the plurality of combustion chambers drives the main shaft of the rotor to rotate by a combustion of a compressed combustible gas mixture. The shell includes an upper cylinder cover and a lower cylinder cover, and a boss of the upper cylinder cover is fitted with a spigot of the lower cylinder cover.

Abstract: An actuator of a rotary engine that can realize different compression ratios includes three parts: an eccentric shaft, a triangle rotor and a control system. The eccentric shaft includes the front part of the eccentric shaft, the combination of an electric three-jaw and the rear part of the eccentric shaft. The triangle rotor includes the variable volume actuator, the front part of the rotor and the rear part of the rotor. The control system controls expansion and contraction of the electric three-jaw. The eccentric shaft part passes through the triangle rotor part to make the combination of electric three jaw to arrange in the annular groove. The reciprocating motion of the variable volume actuator is controlled by the expansion and contraction of the claw top of the electric three-jaw. Engine compression ratio may therefore be adjusted using the compression ratio adjustment system.

Abstract: The present invention provides ocular cells, genetically modified by a CRISPR system targeting the expression of B2M for ocular cell therapy. The invention further provides methods of generating an expanded population of genetically modified ocular cells, for example limbal stem cells (LSCs) or corneal endothelial cells (CECs), wherein the cells are expanded involving the use of a LATS inhibitor and the expression of B2M in the cells has been reduced or eliminated. The present invention also provides a cell populations, preparations, uses and methods of therapy comprising said cells.

Abstract: A composite intake system and method of operating a rotary engine with variable intake manifold is provided. The system includes two switching valves in a secondary intake switching tube to change the intake method. When the rotary engine works under low speed conditions, it adopts the long intake manifold and the side-intake mode. When the rotary engine works under medium and high speed conditions, it uses the short intake manifold and the composite-intake mode. When the rotary engine works under ultra high speed conditions, it takes the short intake manifold and the peripheral-intake mode.

Abstract: The present invention provides an actuator that can realize the different compression ratios of the rotary engine. The invention actuator described above, includes three parts: the eccentric shaft part, the triangle rotor part and the control system. The eccentric shaft part which is described above, includes the front part of the eccentric shaft, the combination of electric three jaw and the rear part of the eccentric shaft. The triangle rotor part which is described above, includes the variable volume actuator, the front part of the rotor and the rear part of the rotor. The control system which is described above, includes the control system of electric three jaw and the rotating joint. The expansion and contraction of the electric three jaw described above, are controlled by the control system of electric three jaw described above.

Abstract: The present invention is related to 6-6 Fused Bicyclic Heteroaryl Compounds of the Formula A2 or A1 and their Use as LATS Inhibitors, or a salt, stereoisomer or pharmaceutical composition thereof; wherein the variables are as defined herein. The present invention further relates to a method of LATS inhibition in a cell population using a compound of Formula A1, or a salt, stereoisomer or pharmaceutical composition thereof. The present invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, their use in the treatment and management of diseases or disorders.

Abstract: Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminum salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.

Abstract: A composite intake system and method of operating a rotary engine with variable intake manifold is provided. The system includes two switching valves in a secondary intake switching tube to change the intake method. When the rotary engine works under low speed conditions, it adopts the long intake manifold and the side-intake mode. When the rotary engine works under medium and high speed conditions, it uses the short intake manifold and the composite-intake mode. When the rotary engine works under ultra high speed conditions, it takes the short intake manifold and the peripheral-intake mode.

Abstract: Disclosed is an imidazole compound, in particular, the compound as shown in formula (I) and a pharmaceutically acceptable salt or tautomer thereof are disclosed.

Abstract: A method for detecting static-current failure devices in a chip is provided. The method includes providing a chip and determining existence of a static-current failure device in the chip. The method also includes detecting positions of a plurality of hotspots in the chip when the existence of the static-current failure devices is determined; and selecting a common circuit path according to position information of the hotspots in a circuit layout file of the chip. Further, the method includes converting a circuit layout of the common circuit path into a corresponding electrical diagram and marking the positions of the plurality of hotspots on corresponding positions on the electrical diagram; and detecting a shared device of the hotspots in the electrical diagram. Further, the method includes marking a position of the shared device in the circuit layout as a position of a static-current failure device.

Abstract: Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.

Abstract: The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 2. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.

Abstract: Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminum salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.

Abstract: A method for detecting static-current failure devices in a chip is provided. The method includes providing a chip and determining existence of a static-current failure device in the chip. The method also includes detecting positions of a plurality of hotspots in the chip when the existence of the static-current failure devices is determined; and selecting a common circuit path according to position information of the hotspots in a circuit layout file of the chip. Further, the method includes converting a circuit layout of the common circuit path into a corresponding electrical diagram and marking the positions of the plurality of hotspots on corresponding positions on the electrical diagram; and detecting a shared device of the hotspots in the electrical diagram. Further, the method includes marking a position of the shared device in the circuit layout as a position of a static-current failure device.

Abstract: The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 2. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.

Abstract: The invention provides a novel class of compounds viz. generally lipopeptides like Pam3CSK4, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 2. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness a vaccine.

Abstract: Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.